IL109802A - Pharmaceutical preparations containing 2 methoxybenzylamines are converted to position N for the treatment of vomiting - Google Patents

Pharmaceutical preparations containing 2 methoxybenzylamines are converted to position N for the treatment of vomiting

Info

Publication number
IL109802A
IL109802A IL10980294A IL10980294A IL109802A IL 109802 A IL109802 A IL 109802A IL 10980294 A IL10980294 A IL 10980294A IL 10980294 A IL10980294 A IL 10980294A IL 109802 A IL109802 A IL 109802A
Authority
IL
Israel
Prior art keywords
alkyl
phenyl
compound
formula
diphenylmethyl
Prior art date
Application number
IL10980294A
Other languages
English (en)
Hebrew (he)
Other versions
IL109802A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL109802A0 publication Critical patent/IL109802A0/xx
Publication of IL109802A publication Critical patent/IL109802A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
IL10980294A 1993-06-04 1994-05-26 Pharmaceutical preparations containing 2 methoxybenzylamines are converted to position N for the treatment of vomiting IL109802A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (2)

Publication Number Publication Date
IL109802A0 IL109802A0 (en) 1994-08-26
IL109802A true IL109802A (en) 2002-04-21

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10980294A IL109802A (en) 1993-06-04 1994-05-26 Pharmaceutical preparations containing 2 methoxybenzylamines are converted to position N for the treatment of vomiting

Country Status (19)

Country Link
US (1) US5393762A (ru)
EP (1) EP0627221B1 (ru)
JP (1) JP2671972B2 (ru)
KR (1) KR100190729B1 (ru)
CN (1) CN1100535C (ru)
AT (1) ATE209490T1 (ru)
AU (1) AU666077B2 (ru)
CA (1) CA2124990C (ru)
DE (1) DE69429208T2 (ru)
DK (1) DK0627221T3 (ru)
ES (1) ES2164088T3 (ru)
HU (1) HU222243B1 (ru)
IL (1) IL109802A (ru)
MY (1) MY115310A (ru)
NZ (1) NZ260674A (ru)
PT (1) PT627221E (ru)
RU (1) RU2135179C1 (ru)
TW (1) TW318791B (ru)
ZA (1) ZA943896B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
ES2092113T3 (es) * 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EP0826684B1 (en) * 1995-03-27 2001-11-21 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
CA2291734A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
CA2352612A1 (en) * 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CZ200434A3 (cs) * 2001-07-20 2005-02-16 Pfizer Products Inc. Léčivo pro léčení abnormálního úzkosného chování u domácích zvířat a způsob screeningu zkoušené sloučeniny za účelem stanovení anxiolytické účinnosti u psů
CA2554346C (en) * 2004-01-30 2009-11-17 Pfizer Products Inc. Parenteral formulations comprising a beta-cyclodextrin and a preservative
US20070155782A1 (en) 2004-01-30 2007-07-05 Hickman Mary A Nk-1 receptor antagonists anesthesia recovery
PT1713801E (pt) * 2004-02-02 2008-02-11 Pfizer Prod Inc Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
ATE113947T1 (de) * 1990-06-01 1994-11-15 Pfizer 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
DK0550635T3 (da) * 1990-09-28 1995-09-04 Pfizer Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser
WO1992012151A1 (en) * 1991-01-10 1992-07-23 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists
ATE115581T1 (de) * 1991-03-01 1994-12-15 Pfizer 1-azabicyclo(3.2.2>nonan-3-aminderivate.
WO1992017449A1 (en) * 1991-03-26 1992-10-15 Pfizer Inc. Stereoselective preparation of substituted piperidines
DE9290057U1 (de) * 1991-05-22 1994-01-05 Pfizer Substituierte 3-Aminochinuclidine
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
ES2092113T3 (es) * 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
TW202432B (ru) * 1991-06-21 1993-03-21 Pfizer
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
CA2118704C (en) * 1991-09-26 1997-01-21 John A. Lowe, Iii Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
CA2324959C (en) * 1991-11-12 2002-11-12 Pfizer Limited Phthalimido compounds as intermediates for producing substance p receptor antagonists
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
CA2134964C (en) * 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
EP1105789A1 (en) * 1998-08-14 2001-06-13 ViA, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
NZ260674A (en) 2000-07-28
EP0627221A3 (en) 1995-08-02
ES2164088T3 (es) 2002-02-16
EP0627221A2 (en) 1994-12-07
US5393762A (en) 1995-02-28
PT627221E (pt) 2002-04-29
HU222243B1 (hu) 2003-05-28
AU666077B2 (en) 1996-01-25
AU6452194A (en) 1994-12-15
DK0627221T3 (da) 2002-02-11
EP0627221B1 (en) 2001-11-28
HU9401676D0 (en) 1994-09-28
MY115310A (en) 2003-05-31
IL109802A0 (en) 1994-08-26
RU94020410A (ru) 1996-05-10
ATE209490T1 (de) 2001-12-15
CN1121806A (zh) 1996-05-08
ZA943896B (en) 1995-12-04
RU2135179C1 (ru) 1999-08-27
KR950000144A (ko) 1995-01-03
CA2124990C (en) 1999-04-20
KR100190729B1 (ko) 1999-06-01
DE69429208D1 (de) 2002-01-10
HUT71550A (en) 1995-12-28
DE69429208T2 (de) 2002-05-23
JP2671972B2 (ja) 1997-11-05
TW318791B (ru) 1997-11-01
CN1100535C (zh) 2003-02-05
JPH0753362A (ja) 1995-02-28

Similar Documents

Publication Publication Date Title
CA2124990C (en) Pharmaceutical agents for treatment of emesis
US20110293640A1 (en) Cholinesterase Inhibitors for Treating Inflammation
CA2405142A1 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
JPH10316567A (ja) 過敏性腸症候群の症状の治療用のｎｋ−１受容体アンタゴニスト
CA2136801C (en) Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5990125A (en) NK-1 receptor antagonists for the treatment of cancer
CA2164804C (en) Nk-1 receptor antagonists for the treatment of neuronal injury and stroke
AU700520B2 (en) NK-1 receptor antagonists for the treatment of cancer
CA2136295A1 (en) Pharmaceutical agents for the inhibition of angiogenesis
EP0653208A2 (en) Pharmaceutical agents for treatment or prevention of sunburn
EP0790825A1 (en) Nk-1 receptor antagonists for the treatment of eye disorders
KR19980080824A (ko) 지연성 구토 치료를 위한 ｎｋ-1 수용체 길항제
WO2002007714A2 (en) Use of anellated dihydropyridines for the preparation of pharmaceutical compositions for the treatment of chronic pain
JPH09110721A (ja) Ｎｋ−１受容体アンタゴニストを用いる抗嘔吐治療用の組み合わせ
CA2324116A1 (en) Nk-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees